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Abstract
Background: Management of preterm labor by tocolysis remains an unmet medical need.
Prostaglandins play a major role in regulation of uterine activity and in molecular mechanisms of
human labor and parturition. There is some circumstantial evidence that prostaglandin F2α by
action through the prostaglandin receptor subtype FP is effective in key events during labor uterine
contraction, rupture of membranes and cervical dilation. This role of FP is briefly reviewed. In this
study, we tested the hypothesis that an orally active and selective FP antagonist may arrest labor
and delay parturition in animal models.
Methods: We examined the effects of a small molecule selective antagonist of the FP receptor
(AS604872) in inhibition of spontaneous uterine contraction in pregnant rat near term. We tested
AS604872 for its ability to delay preterm birth in a mouse model in which the anti-progestin agent
RU486 triggered parturition.
Results: By oral or intravenous dosing AS604872 reduced markedly and dose-dependently the
spontaneous uterine contractions in late-term pregnant rats at gestational days 19–21. In pregnant
mice, AS604872 delayed the preterm birth caused by RU486 administration. The effect was dose-
dependent with a significant increase in the mean delivery time of 16 and 33 hours at oral doses of
30 mg/kg and 100 mg/kg, respectively, in the case of labor triggered at gestational day 14. In both
models AS604872 appeared more effective than the β-agonist ritodrine.
Conclusion: The tocolytic activity displayed by a selective FP receptor antagonist supports a key
role for the FP receptor in the pathophysiology of premature birth and demonstrates the
therapeutic potential of an FP antagonist for the treatment of preterm labor cases in which uterine
hyperactivity plays a dominant role.
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Preterm birth is a serious health problem that remains the
major cause of perinatal mortality and morbidity [1].
Spontaneous preterm labor is the major cause of prema-
ture birth. Despite important advances in our understand-
ing of the mechanism of human parturition and the
pathophysiology of preterm labor, there has been very lit-
tle progress in the prediction, prevention and therapeutic
management of preterm labor. Preterm increase of uterine
activity is the most common expression of preterm labor.
Therefore, pharmacological interventions aimed at main-
taining uterine quiescence have been given much atten-
tion for the pharmaceutical management of preterm labor
[2]. Tocolytic agents arrest preterm labor and prolong
pregnancy up to a few days at the most but often with
adverse effects on women and without clear demonstra-
tion of improvement in neonatal outcome [3,4].
Prostaglandins play a major role during pregnancy and
parturition in all studied species, including human. In
particular prostaglandins are involved, directly or through
modulation of other endocrine or paracrine factors, in the
final common pathway of preparation, activation and
stimulation of uterine tissues leading to onset of labour
[5-9]. Levels of prostaglandins in uterine tissues vary in
time and regionally under the control of their synthesis by
cyclooxygenases isozymes COX-1 and COX-2 and specific
prostaglandin synthases on one hand and their metabo-
lism by prostaglandin dehydrogenase enzymes on the
other hand. Prostaglandins exert their effects through at
least nine G protein-coupled receptor subtypes EP1-4, IP,
FP, TP, DP, CRTH2 or DP2, some of them (EP1, EP3, FP,
TP) existing as multiple splice variants [10,11]. PGE2 has
dual uterotonic effects by action through EP1 and EP3 but
may also exert an uterorelaxant effect through EP2 and
EP4.
Prostaglandin F2α (PGF2α) contracts the myometrium in
vitro and in vivo through activation of FP. Activation of FP
[12] in the human myometrium by PGF2α results in the
elevation of intracellular calcium concentration, which, in
turn, leads to contraction of the uterine smooth cell mus-
cle [13]. FP receptor protein expression increases in the rat
myometrium with advancing gestational age thus enhanc-
ing sensitivity of the myometrium to PGF2α contractile
action [14]. Likewise, FP is expressed in term human myo-
metrium [13,15,16]. PGF2α has been shown to induce up-
regulation of matrix metalloproteinase MMP1, an enzyme
that breaks down collagen in cervical fibroblasts leading
to cervical ripening [17]. PGF2α upregulates MMP-2 and
MMP-9 and downregulates their naturally-occurring
inhibitor TIMP-1 in human term decidua, thus accelerat-
ing the breakdown of collagen and the rupture of mem-
branes [18]. PGF2α potentiates cortisol production by
stimulating the enzyme 11β-hydroxysteroid dehydroge-
nase 1. Cortisol increases prostaglandin synthesis and
decreases prostaglandin metabolism in human chorion
trophoblasts thus creating a feed-forward loop in fetal
membranes that may contribute to preterm birth [19].
Taken together all these findings strongly suggest that
blocking FP activation might be beneficial for the control
of preterm labour. Potentially, a tocolytic agent based on
selective FP antagonism may be devoid of the side effects
that were observed in the clinic with COX-1 and COX-2
inhibitors [20,21]. To test this hypothesis we have evalu-
ated the effect of a recently identified orally active, potent
and highly selective small molecule antagonist of the FP
receptor (AS604872) in two rodent models of uterine





boxamide was chemically synthesized at the Serono Phar-
maceutical Research Institute (Geneva, Switzerland). In
all the in vivo experiments AS604872 was administered in
NP3S (5% N-methylpyrrolidone, 25% polyethylene gly-
col 200, 30% polyethylene glycol 400, 20% propylene
glycol, 20% saline), while ritodrine was solubilized in
saline.
In vivo experiments
All the in vivo experiments were performed according to
the European Council Directive 86/609/EEC and the Ital-
ian Health Ministry guidelines for the care and use of
experimental animals (decree 116/92).
Uterine contraction model
Sprague Dawley CD (SD) BR non-pregnant (200–300 g)
or late-term certified pregnant (19–21 gestation days;
350–400 g) female rats from Charles River, Calco, (Italy)
were used. PGF2α- or oxytocin-induced uterine contrac-
tions in anaesthetized non-pregnant rats and spontaneous
uterine contractions in anaesthetized late-term rats were
all performed as described previously [22].
Mouse preterm parturition model
Time-mated, primigravid certified pregnant CD1 mice
transferred from Charles River (Calco, Italy) to our animal
facility at day 11 of gestation were used. Preterm labor was
induced according to previous reports with some modifi-
cations [23,24]. In detail, pregnant mice at gestational day
14 or 17 were treated subcutaneously with RU486 (mife-
pristone) 2.5 mg/kg/5 ml at 1:00 PM. Randomly defined
subgroups of animals (n = 8–10/dose) were then treated
twice daily orally with AS604872 (10-30-100 mg/kg) or
ritodrine (30–100 mg/kg), or the vehicle (NP3S or saline
5 ml/kg) for a total of 4 administrations (6 PM on the
same day of RU486 treatment, 8 AM and 6 PM on the nextPage 2 of 5
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0 1 2 0day and 8 AM on the day after). Each animal was checked
for the occurrence of delivery starting from 18 hours after
RU486 treatment, every three hours during the light
phase, and every six hours during the dark phase. Delivery
time was defined as the time of the first pup presence. The
pups delivered were scored and classified as abortions,
pups born alive and pups born dead. Since some of the
pups may die during the time elapsing between our
inspections, all the dead pups were controlled by the
galenic hydrostatic pulmonary docimasy. The dead pups
were dissected and a portion of the lung placed in water.
Lung floating over the water indicated air content, and the
ability of the pup to breathe after birth. The mean delivery
time after RU486 was calculated based on the individual
time of first pup delivery for each treatment.
Statistical analysis
All data are means ± SEM. Statistical analysis was per-
formed by one-way ANOVA, followed by Tukey's test. Sta-
tistics were performed using S-Plus2000 (MathSoft Inc.,
Seattle, Washington, USA) and significance assumed at
the 5% level.
Results
The potent and selective FP antagonist AS604872 (Ki
human FP, 35 nM; rat FP, 158 nM, mouse, FP 323 nM;
selectivity vs EP2 50-fold and >1,000-fold vs other prosta-
noid receptors) reduced markedly and dose-dependently
the spontaneous uterine contractions in late-term preg-
nant rats at gestational days (GD) 19–21 (Figure 1). Intra-
venous injection at the two highest doses (1 and 3 mg/kg/
min for 10 min infusion corresponding to a total dose of
10 and 30 mg/kg, respectively) inhibited uterine contrac-
tility by about 37 and 53%, respectively. By oral dosing,
AS604872 was also able to reduce the spontaneous uter-
ine contractions by around 28% and 32% of the pre-dose
value at doses of 30 and 60 mg/kg, respectively (Figure 1).
The inhibiting effect by oral route peaked at about 30 min
after administration and remained at a sustained level up
to the end of the observation period of 3 h (data not
shown). The intravenous administration of ritodrine
decreased the spontaneous uterine motility by about 25%
without a dose-dependent relationship, whereas a dose of
120 mg/kg by oral route was ineffective (Figure 1).
Oral treatment with AS604872 delayed the preterm birth
caused by RU486 (mifepristone) administration in preg-
nant mice at GD 14 or GD17. The effect was dose-depend-
ent with a significant increase in the mean delivery time of
16 and 33 hours at doses of 30 mg/kg and 100 mg/kg,
respectively, in the case of labor triggered at GD14 (Figure
2). The parturition retardation effect of AS604872 on
labor induced at GD17 was less marked with a delay of 16
hours at 100 mg/kg (Figure 3). In this model AS604872
was more effective than ritodrine at GD17 whereas both
compounds were comparable at GD14.
In the RU486 preterm parturition model, as an important
consequence of the prolongation of gestation, some dams
treated with AS604872 or ritodrine delivered viable pups
(Figure 4). The proportion of live pups was higher in the
GD17 than in the GD14 model. Remarkably, when labor
was induced at GD17, 44% of the 100 mg/kg AS604872
treated animals delivered viable pups compared to only
11% in the group treated with 100 mg/kg ritodrine. All the
other deliveries resulted in abortions.
Discussion
We have used a potent and selective small molecule antag-
onist of the FP receptor to decipher the role of this prosta-
noid receptor subtype in preterm labor and parturition. It
was known that FP-deficient mice showed impaired par-
turition by lack of luteolysis and consequently absence of
progesterone withdrawal, a necessary event to trigger
labor in most animal species [25]. One key finding of our
study was that blocking FP had also a clear effect on the
myometrium through inhibition of uterotonic pathways
in the pregnant rat model of uterine contractility. It is
interesting to note that uterine activity was not fully abol-
ished by treatment with AS604872, suggesting that other
biochemical pathways are likely to be activated towards
term and underlying the complex pathophysiology of pre-
term delivery. In the mouse parturition model, the induc-
Effects of AS604872 and ritodrine on inhibition of spontane-ous uterine contractions in pregnant ratsFigur  1
Effects of AS604872 and ritodrine on inhibition of 
spontaneous uterine contractions in pregnant rats. 
Anesthetized late-term pregnant rats at gestational days 19–
21 were treated with AS604872 or ritodrine either by intra-
venous route as a 10-min infusion or orally as a single dose. 
The inhibition of spontaneous uterine contractions is repre-
sented in function of the dose of drugs. N = 8 animals per 
dose and route and drug. *p < 0.05, **p < 0.01 and ***p < 
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(RU486) activates endocrine pathways and a drop in pro-
gesterone level characterized by the up-regulation of
labor-associated proteins as seen in the case of idiopathic
preterm labor. The FP antagonist AS604872 delayed par-
turition triggered by RU486 thus indicating that FP plays
a central role in preterm labor of endocrine etiology.
There was a trend towards better tocolytic efficacy of
AS604872 at GD14 compared to GD17. This may suggest
that other biochemical pathways to labor and parturition
are activated at advanced gestational age. One key obser-
vation was the enhanced viability of pups delivered by
mice treated with AS604872, thus underlying the benefi-
cial effect of prolonging gestation. In both models,
AS604872 was benchmarked against the β-mimetic rito-
drine that has been commonly used as tocolytic agent.
There was a clear trend towards superior activity for
AS604872.
Our findings support recent reports that used a non-com-
petitive, non-selective and injectable FP peptide antago-
nist in sheep and human myometrial strips [26,27].
Conclusion
The tocolytic activity displayed by the selective antagonist
AS604872 supports a key role for the FP receptor in the
pathophysiology of premature birth and demonstrates the
therapeutic potential of an FP antagonist for the treatment
of preterm labor cases in which uterine hyperactivity plays
a dominant role.
List of abbreviations
FP, prostaglandin F2α receptor; COX-1, COX-2, cyclooxy-
genase 1 or 2; PGF2α, prostaglandin F2α; GD, gestation
day; MMP, matrix metallo-proteinase; TIMP, tissue inhib-
itor of matrix metallo-proteinase.
Effects of AS604872 and ritodrine on viability of preterm mouse pupFig re 4
Effects of AS604872 and ritodrine on viability of pre-
term mouse pup. Data are expressed as % of dams that 
delivered live pups following labor induction by RU486 at 
GD14 or GD17 and treatment with different oral doses of 
AS604872 or ritodrine. The mean total number of pups 
(abortion, born dead and born alive) for each treatment 



































Delaying effect of AS604872 and ritodrine on preterm partu-rition in mice induced at GD14Figure 2
Delaying effect of AS604872 and ritodrine on pre-
term parturition in mice induced at GD14. Preterm 
parturition was induced by subcutaneous treatment with 
RU486 (mifepristone) at GD 14. Then different doses of 
AS604872 or ritodrine were administered orally b.i.d. and 
time to delivery was monitored (see Methods). Data are 
expressed as mean time to delivery ± SEM from the induc-

























Delaying effect of AS604872 and ritodrine on preterm partu-rition in mice induced at GD17Figure 3
Delaying effect of AS604872 and ritodrine on pre-
term parturition in mice induced at GD17. Preterm 
parturition was induced by subcutaneous treatment with 
RU486 (mifepristone) at GD 17. Then different doses of 
AS604872 or ritodrine were administered orally b.i.d. and 
time to delivery was monitored (see Methods). Data are 
expressed as mean time to delivery ± SEM from the induc-
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